Crizotinib (trade name Xalkori Pfizer) is an anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor approved for treatment of some non-small cell lung carcinoma (NSCLC) in the US and some other countries and undergoing clinical trials testing its safety and efficacy in anaplastic large cell lymphoma neuroblastoma and other advanced solid tumors in both adults and children.
This page contains content from the copyrighted Wikipedia article "Crizotinib"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
